Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences (NASDAQ: AKYA), The Spatial Biology Company®, announce a definitive merger agreement under which Quanterix will acquire Akoya in an all-stock transaction. The transaction will create the first integrated solution for ultra-sensitive detection of blood- and tissue-based protein biomarkers. “Liquid biopsy will eventually surpass the market size of all other diagnostics testing combined. Enabling early disease detection, before symptoms appear, using non-invasive methods is our mission and will be the majority of Quanterix’s long-term value,” said Masoud Toloue, PhD, Chief Executive Officer of Quanterix.
Read the full article: Quanterix to Acquire Akoya Biosciences //
Source: https://www.businesswire.com/news/home/20250110529120/en/Quanterix-to-Acquire-Akoya-Biosciences-Creating-the-First-Integrated-Solution-for-Ultra-Sensitive-Detection-of-Blood–and-Tissue-Based-Protein-Biomarkers